key: cord-0910035-f3b4xini
authors: Taira, Naoyuki; Toguchi, Sakura; Miyagi, Mio; Mori, Tomoari; Tomori, Hiroaki; Oshiro, Koichi; Tamai, Osamu; Kina, Mitsuo; Miyagi, Masatake; Tamaki, Kentaro; Collins, Mary K; Ishikawa, Hiroki
title: Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals
date: 2021-12-23
journal: Clinical Immunology Communications
DOI: 10.1016/j.clicom.2021.12.001
sha: 292e87c0fcda31fe036bbfec53534733e5646220
doc_id: 910035
cord_uid: f3b4xini

Pre-existing SARS-CoV-2-specific T cells, but not antibodies, have been detected in some unexposed individuals. This may account for some of the diversity in clinical outcomes ranging from asymptomatic infection to severe COVID-19. Although age is a risk factor for COVID-19, how age affects SARS-CoV-2-specific T cell responses remains unknown. We found that pre-existing T cell responses to specific SARS-CoV-2 proteins, Spike (S) and Nucleoprotein (N), were significantly lower in elderly donors (>70 years old) than in young donors. However, substantial pre-existing T cell responses to the viral membrane (M) protein were detected in both young and elderly donors. In contrast, young and elderly donors exhibited comparable T cell responses to S, N, and M proteins after infection with SARS-CoV-2. These data suggest that although SARS-CoV-2 infection can induce T cell responses specific to various viral antigens regardless of age, diversity of target antigen repertoire for long-lived memory T cells specific for SARS-CoV-2 may decline with age; however, memory T cell responses can be maintained by T cells reactive to specific viral proteins such as M. A better understanding of the role of pre-existing SARS-CoV-2-specific T cells that are less susceptible to age-related loss may contribute to development of more effective vaccines for elderly people.

There is extensive individual variation in severity of coronavirus disease 2019 , caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), ranging from asymptomatic infection to fatal pneumonia [1] . Various factors, including age, sex, and comorbidities such as obesity and diabetes, influence the risk of severe COVID-19 [2] [3] [4] . For example, morbidity and mortality among the elderly are significantly higher than among the young [2] . Consideration of protective measures for individuals vulnerable to COVID-19 should be particularly important to control the pandemic [5] . However, cellular and molecular bases of variable risk of COVID-19 disease remain poorly understood.

T cells are assumed to mediate both protective and pathogenic immune responses to SARS-CoV-2 infection [6, 7] . The magnitude and quality of T cell responses induced by SARS-CoV-2 infection are highly heterogeneous and are likely associated with COVID-19 clinical outcomes. For example, SARS-CoV-2-specific T cell numbers and their interferon- (IFN-) expression in severe COVID-19 patients are lower than in mild COVID-19 patients [8, 9] . Furthermore, asymptomatic COVID-19 patients tend to have increased SARS-CoV-2-specific T cells expressing higher levels of IFN- compared to symptomatic patients [10] . This individual variation in T cell responses may be partly explained by heterogeneity in levels of pre-existing SARS-CoV-2-reactive T cells.

Some individuals who have not been exposed to SARS-CoV-2 have nonetheless acquired SARS-CoV-2-reactive T cells, probably through exposure to other common cold coronaviruses [11] [12] [13] . Pre-existing CD4 and CD8 memory T cells, specific to various SARS-CoV-2 proteins, including the structural proteins, Spike (S), Membrane (M), and Nucleoprotein (N), have been detected with significant individual variation, and these pre-existing SARS-CoV-2-reacive T cells are likely associated with immune protection against COVID-19 [14] ; however, in other cases, they may exacerbate COVID-19 severity [15, 16] . As many of the current vaccines express the SARS-CoV-2 S protein, only pre-existing S-reactive T cells are activated by these vaccines [17, 18] . Several studies have reported age-related differences in SARS-CoV-2-specific T cell responses in COVID-19 patients [19, 20] ; however, the effect of age on pre-existing SARS-CoV-2-reactive T cells remains unknown.

In this study, we compared frequencies of T cells reactive to SARS-CoV-2 S, N, and M antigens between young and elderly donors. The relatively elderly Okinawan population, and the moderate rate of SARS-CoV-2 infection in Okinawa, allowed us to examine pre-existing SARS-CoV-2-specific T cells in a cohort of elderly (>70 years old) individuals. We found that pre-existing T cell responses to S and N antigens are significantly impaired in elderly donors compared to young donors, but a proportion of elderly donors exhibit significant, high levels of M-reactive T cell responses. These data provide new insights into age-related alteration of pre-existing SARS-CoV-2-specific T cells.

The study design was approved by the Okinawa Institute of Science and Technology, Graduate University (OIST) human subjects ethics committee (applications HSR-2020-024, HSR-2020-028). All donors provided informed written consent. Young 1-3 months before blood collection.

Blood samples were collected in heparin-coated tubes (TERUMO;

VP-H100K). PBMCs and plasma were separated using Leucosep tubes pre-filled with Ficoll-Paque Plus (Greiner; 163288). After adding 5 mL of blood and 3 mL of AIM-V medium (Thermo; 12055091), Leucosep tubes were centrifuged at 1,000 g at room temperature for 10 min. The white layer containing PBMCs was collected, washed with 10 mL AIM-V medium and centrifuged for 7 min at 600 g, followed by a second washing with centrifugation for 7 min at 400 g. PBMC pellets were resuspended in 500

L CTL test medium (Cellular Technology Limited (CTL); CTLT-010). Fresh PBMCs were used for IFN-ELISpot assays. PBMCs used for flow cytometry analysis and epitope mapping analysis were stored with CTL-cryo ABC media (CTL; CTLC-ABC) in liquid nitrogen.

Plasma from each donor was first tested using Cellex qSARS-Cov-2 IgG/IgM Cassette Rapid Tests (Cellex 5513C). Plasma from donors who had positive test results in the first test was subsequently retested using SARS-CoV-2 Antibody Detection Kits (KURABO RF-NC001, RF-NC002).

Peptide PBMCs (the mean of negative control SFU + 3 standard deviations) was used as the cut-off for positivity in the ELISpot test.

Mann-Whitney U tests were performed using GraphPad Prism 9.1.0 software. Statistical details are provided in figure legends.

To assess whether there are age-related differences in SARS-CoV-2-specific T cell responses, we collected peripheral blood from young (20 to 50 years of age) and elderly 

Our data indicate that a fraction of elderly donors possess significantly high levels of pre-existing SARS-CoV-2 M-specific T cell responses, though the frequency of pre-existing SARS-CoV-2 S-and N-specific T cells is lower in elderly than young donors. Other recent studies have also reported an age-related decline of S-specific pre-existing CD4 T cells [18, 21] . On the other hand, another study reported that there are no significant differences in the frequency of the pre-existing CD4 and CD8 T cells that are responsive to mixed peptide pools covering S, N, and M proteins between young and elderly donors, although the SARS-CoV-2-responsive naïve CD8 T cells are less numerous in elderly than young [22] . These data suggest that pre-existing T cells specific for SARS-CoV-2 are heterogeneously affected by age in a target antigen-dependent manner and that diversity of the target antigen repertoire for pre-existing T cells may decline with age, but the magnitude of pre-existing T cell responses can be maintained with T cells specific to certain viral proteins, such as M.

As the frequency of pre-existing T cells specific to viral structural proteins S, N, and M is likely associated with protection from SARS-CoV-2 infection [14] , focused M-specific T cell responses might be particularly important for protection of elderly individuals who have lower T cell responses to S and N. We speculate that pre-existing

immunity through IFN- production and by providing T cell help to S-and N-specific B cells via linked recognition. However, we cannot exclude the possibility that pre-existing M-specific T cells are harmful for some elderly individuals. Several studies suggest that pre-existing SARS-CoV-2-specific T cells are detrimental in COVID-19 [23] . In particular, the frequency of M-specific T cells in COVID-19 patients is thought to be a risk factor, as it is correlated with age and severity of disease [8] , [21] . Importantly, several peptides derived from these coronaviruses are cross-reactive with SARS-CoV-2-specific pre-existing T cells [27] . The decrease of memory T cells specific to common cold coronavirus S proteins in elderly donors [21] can account for the decrease of SARS-CoV-2-specific pre-existing T cells. We speculate that memory T cells specific to common cold coronavirus M proteins, which are cross-reactive to SARS-CoV-2 M, might be resistant to age-related decline [21] .

It is worth considering the potential of novel COVID-19 vaccines to induce M-specific immunity. Current vaccine strategies are to induce S-specific antibody and T cell responses [28, 29] . Recent studies reported a correlation between the frequency of pre-existing S-specific T cells and vaccine-induced S-specific T cell responses [18] , which suggests a role of pre-existing S-specific T cells in cognate T cell help. However, elderly individuals likely would not benefit fully from pre-existing S-specific T cells. To enhance vaccine efficacy among the elderly, it might be reasonable to consider a strategy to induce not only S-specific, but also M-specific immunity, using vaccines based on inactivated viruses or M-fused S antigens. Linked recognition of M-specific T helper cells by S-specific B cells can promote S-specific antibody production by overcoming the defect of cognate T cell help in elderly individuals. Further characterization of M-specific T cells in young and elderly may provide new insights into vaccine-induced immunity that is less affected by age. 

Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages

Age-specific mortality and immunity patterns of SARS-CoV-2

Sex differences in immune responses that underlie COVID-19 disease outcomes

Global pandemics interconnected -obesity, impaired metabolic health and COVID-19

Controlling the pandemic during the SARS-CoV-2 vaccination rollout

Warriors of SARS-CoV-2 Infection

SARS-CoV-2-specific T cell responses and correlations with COVID-19 patient predisposition

Clinical and immunological features of severe and moderate coronavirus disease

Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection

SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19

SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls

Healthy donor T cell responses to common cold coronaviruses and SARS-CoV-2

CoV-2 responsive T cell numbers and anti-Spike IgG levels are both associated with protection from COVID-19: A prospective cohort study in keyworkers

Low-Avidity CD4(+) T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19

T cell responses in patients with COVID-19

COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses

Cross-reactive CD4+ T cells enhance SARS-CoV-2 immune responses upon infection and vaccination

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

SARS-CoV-2 specific T cell responses are lower in children and increase with age and time after infection

Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63

Aging and CMV Infection Affect Pre-existing SARS-CoV-2-Reactive CD8+ T Cells in Unexposed Individuals

Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid SARS

Proteins Is Not Associated with Recovery in Critical COVID-19 Patients

Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection

SARS-CoV-2-specific T cells are rapidly expanded for therapeutic use and target conserved regions of the membrane protein

Recent endemic coronavirus infection is associated with less-severe COVID-19

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans

SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

The authors have no conflict of interest

We thank physicians and nurses at KIN Oncology Clinic for excellent support in 15 collecting blood samples from donors. We also thank Steven Aird for editing the manuscript. We are also grateful to OIST Graduate University for its generous funding of the Immune Signal Unit.